Amgen has revealed new Phase 3 data for the combination of Kyprolis (carfilzomib) and Darzalex (daratumumab) in addition to the steroid dexamethasone, showing that the combo met its primary endpoint of progression-free survival (PFS) in the treatment of multiple myeloma (MM) compared to Kyprolis and dexamethasone alone.
The findings showed that the three-drug regimen reduced the risk of progression or death in patients with relapsed or refractory MM by 37% compared to the two-drug combination.
